Morphogenesis announces clinical trials
For promising equine cancer vaccine

Horses indicating melanoma needed as candidates for this major clinical study

TAMPA – Morphogenesis Inc., the biotechnology firm that has developed a side-effect-free cancer vaccine that has improved the longevity and quality of life for dogs, cats and horses, announces that formal equine clinical trials for its ImmuneFx™ cancer vaccine begin in September at a large equine boarding facility in Kansas.

Pat Lawman, PhD., co-founder and CEO of Morphogenesis, said horses indicating the presence of equine melanoma are needed for the study. Owners whose horses exhibit signs of the disease should check with their veterinarian to determine if their animal is a candidate for the clinical trials.

Expected to last about a year, the formal clinical trials are designed to precisely assess the efficacy and safety of the ImmuneFx™ cancer vaccine in horses. Individual investors are welcomed to help fund the clinical trials.

“We have had some major successes in reducing equine melanoma in the cases we have treated to date, and depending on the results, these formal clinical trials will statistically and scientifically establish the reliability of the therapy,” said Lawman.

ImmuneFx™ has been shown to be effective against more than 20 different types of cancers in dogs, cats and horses. ImmuneFx™ has been authorized by the USDA for application in companion animal cancer treatment programs.

Plans call for ImmuneFx™ to be in human clinical trials in January.

ABOUT MORPHOGENESIS

Morphogenesis Inc. (www.morphogenesis-inc.com) is a 19-year-old, privately-held biotechnology company that is conducting ground-breaking research in the rapidly growing cell therapy, biologics and tissue engineering fields. The company has received more than $9 million in financial support from grantors and private investors around the world.

The co-founders of Morphogenesis hold more than 20 U.S. patents and have several more pending. Morphogenesis has developed, and is primarily focused on, its multi-indication therapeutic cancer vaccine, ImmuneFx™, which educates the patient’s own immune system to attack tumor cells throughout the body without damaging normal cells or systems.

ABOUT THE IMMUNOLOGY MARKET

Several leading authorities project the annual therapeutic cancer vaccine market to expand to $8 billion within the next six years. Immunotherapy revenues worldwide are predicted to reach $35 billion in 10 years. Experts predict that within the next 10 years, 50 percent of cancer treatments will involve immunotherapy.

*****